Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Leerink Partners Raises Price Target on Ironwood Pharma (IRWD) to $14; Reiterates Market Perform
August 5, 2016 9:03 AM EDTLeerink Partners reiterated a Market Perform rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $14.00 (from $10.00), following the company's 2Q earnings report. Linzess sales grew to $150.5m, ~2% above forecasts. Underlying sales growth of +34% was driven by 29% Rx volume growth. IRWD will launch Zurampic (gout) in October 2016. Zurampic... More
Ironwood Pharma (IRWD) Misses Q2 EPS by 1c
August 4, 2016 4:19 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $54.4 million versus the consensus estimate of $55.46 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More